263 related articles for article (PubMed ID: 24252799)
21. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
22. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
Haruyama Y; Kataoka H
World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
25. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Tsuchiya N; Hosono A; Yoshikawa T; Shoda K; Nosaka K; Shimomura M; Hara J; Nitani C; Manabe A; Yoshihara H; Hosoya Y; Kaneda H; Kinoshita Y; Kohashi K; Yoshimura K; Fujinami N; Saito K; Mizuno S; Nakatsura T
Oncoimmunology; 2017; 7(1):e1377872. PubMed ID: 29296538
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.
Sawada Y; Yoshikawa T; Ofuji K; Yoshimura M; Tsuchiya N; Takahashi M; Nobuoka D; Gotohda N; Takahashi S; Kato Y; Konishi M; Kinoshita T; Ikeda M; Nakachi K; Yamazaki N; Mizuno S; Takayama T; Yamao K; Uesaka K; Furuse J; Endo I; Nakatsura T
Oncoimmunology; 2016 May; 5(5):e1129483. PubMed ID: 27467945
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Cancer Immunotherapy Targeting Glypican-3.
Shimizu Y; Suzuki T; Yoshikawa T; Endo I; Nakatsura T
Front Oncol; 2019; 9():248. PubMed ID: 31024850
[TBL] [Abstract][Full Text] [Related]
29. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
[TBL] [Abstract][Full Text] [Related]
30. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
32. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.
Iwama T; Horie K; Yoshikawa T; Nobuoka D; Shimomura M; Sawada Y; Nakatsura T
Int J Oncol; 2013 Mar; 42(3):831-8. PubMed ID: 23354275
[TBL] [Abstract][Full Text] [Related]
33. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
Tsuchiya N; Yoshikawa T; Fujinami N; Saito K; Mizuno S; Sawada Y; Endo I; Nakatsura T
Oncoimmunology; 2017; 6(10):e1346764. PubMed ID: 29123959
[TBL] [Abstract][Full Text] [Related]
34. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
35. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
37. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth.
Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F
Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906
[TBL] [Abstract][Full Text] [Related]
38.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M; Hazama S; Tamada K; Udaka K; Kouki Y; Uematsu T; Arima H; Saito A; Doi S; Matsui H; Shindo Y; Matsukuma S; Kanekiyo S; Tokumitsu Y; Tomochika S; Iida M; Yoshida S; Nakagami Y; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Ueno T; Nagano H
Cancer Immunol Immunother; 2020 Aug; 69(8):1651-1662. PubMed ID: 32219501
[TBL] [Abstract][Full Text] [Related]
40. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
